New triple therapy aims to wipe out Hard-to-Treat leukemia
NCT ID NCT02846623
First seen Feb 17, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the combination can make the cancer undetectable in the bone marrow (called MRD-negative). Participants receive the drugs intravenously and orally over several months, and researchers monitor side effects and treatment response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.